JP2018504144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504144A5 JP2018504144A5 JP2017557490A JP2017557490A JP2018504144A5 JP 2018504144 A5 JP2018504144 A5 JP 2018504144A5 JP 2017557490 A JP2017557490 A JP 2017557490A JP 2017557490 A JP2017557490 A JP 2017557490A JP 2018504144 A5 JP2018504144 A5 JP 2018504144A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- cll1
- antigen receptor
- chimeric antigen
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 claims 9
- 101150031358 COLEC10 gene Proteins 0.000 claims 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 102100024206 Collectin-10 Human genes 0.000 claims 9
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570044 | 2015-01-26 | ||
| DKPA201570044 | 2015-01-26 | ||
| PCT/EP2016/051470 WO2016120219A1 (en) | 2015-01-26 | 2016-01-25 | Cll1-specific multi-chain chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504144A JP2018504144A (ja) | 2018-02-15 |
| JP2018504144A5 true JP2018504144A5 (https=) | 2019-03-07 |
Family
ID=52396337
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557489A Active JP6779909B2 (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ） |
| JP2017557491A Pending JP2018504145A (ja) | 2015-01-26 | 2016-01-25 | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
| JP2017557490A Withdrawn JP2018504144A (ja) | 2015-01-26 | 2016-01-25 | Ｃｌｌ１特異的多鎖キメラ抗原受容体 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557489A Active JP6779909B2 (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ） |
| JP2017557491A Pending JP2018504145A (ja) | 2015-01-26 | 2016-01-25 | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20180000914A1 (https=) |
| EP (5) | EP3250602A1 (https=) |
| JP (5) | JP6884709B2 (https=) |
| KR (3) | KR102661969B1 (https=) |
| CN (5) | CN107438618A (https=) |
| AU (5) | AU2016212161A1 (https=) |
| BR (2) | BR112017013981A2 (https=) |
| CA (4) | CA2973532A1 (https=) |
| DK (2) | DK3250606T3 (https=) |
| ES (2) | ES2869972T3 (https=) |
| IL (3) | IL252937B (https=) |
| MX (3) | MX381908B (https=) |
| RU (3) | RU2731543C2 (https=) |
| WO (5) | WO2016120218A1 (https=) |
Families Citing this family (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| CA2943008C (en) | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| EP3283520B1 (en) | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| JP7115982B2 (ja) | 2015-10-30 | 2022-08-09 | アレタ・バイオセラピューティクス・インコーポレイテッド | 癌の治療のための組成物及び方法 |
| KR20180083868A (ko) | 2015-10-30 | 2018-07-23 | 알레타 바이오쎄라퓨틱스, 인크. | 종양 형질도입용 조성물 및 방법 |
| CN105331586B (zh) * | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| CN108290955A (zh) * | 2015-11-24 | 2018-07-17 | 塞勒兰特治疗公司 | 人源化抗-cll-1抗体 |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| US11104738B2 (en) | 2016-04-04 | 2021-08-31 | Hemogenyx Pharmaceuticals Llc | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
| WO2017176760A2 (en) | 2016-04-04 | 2017-10-12 | Vladislav Sandler | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| JP7195154B2 (ja) | 2016-07-06 | 2022-12-23 | セレクティス | 初代免疫細胞における逐次遺伝子編集 |
| WO2018035330A1 (en) * | 2016-08-19 | 2018-02-22 | Janssen Biotech, Inc. | Methods of treating crohn's disease with an anti-nkg2d antibody |
| WO2018057915A1 (en) | 2016-09-23 | 2018-03-29 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| ES2925644T3 (es) * | 2016-10-04 | 2022-10-19 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células modificadas genéticamente |
| CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| AU2017382883B2 (en) | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| EP3601346A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| EP4414380A3 (en) | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| EP3490605B1 (en) * | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP7317718B2 (ja) | 2017-06-02 | 2023-07-31 | ファイザー・インク | Ｆｌｔ３を標的にするキメラ抗原受容体 |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| CA3287539A1 (en) * | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| US12144825B2 (en) | 2017-06-30 | 2024-11-19 | Cellectis | Cellular immunotherapy for repetitive administration |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| CA3070409A1 (en) | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting cd33-expressing cancers |
| WO2019016360A1 (en) | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| CN111432823A (zh) * | 2017-07-25 | 2020-07-17 | 得克萨斯大学体系董事会 | 增强的嵌合抗原受体及其用途 |
| WO2019020733A1 (en) | 2017-07-26 | 2019-01-31 | Cellectis | METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR) |
| MX2020004185A (es) | 2017-09-27 | 2021-01-08 | Univ Southern California | Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva. |
| WO2019072824A1 (en) | 2017-10-09 | 2019-04-18 | Cellectis | IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109836496A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109837303A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| JP2021508468A (ja) * | 2017-12-29 | 2021-03-11 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | メディトープ対応ｔ細胞 |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| CN109608548A (zh) * | 2017-12-29 | 2019-04-12 | 郑州大学第附属医院 | 基于人源cd20抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| AU2018396083B2 (en) | 2017-12-29 | 2025-09-25 | Cellectis | Method for improving production of CAR T cells |
| WO2019139888A1 (en) * | 2018-01-09 | 2019-07-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
| PE20210708A1 (es) | 2018-02-01 | 2021-04-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| KR102780406B1 (ko) * | 2018-02-01 | 2025-03-17 | 화이자 인코포레이티드 | Cd70을 표적으로 하는 키메라 항원 수용체 |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN111918877A (zh) * | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
| US20210070860A1 (en) * | 2018-03-21 | 2021-03-11 | Dana-Farber Cancer Institute, Inc. | Fc variant compositions and methods of use thereof |
| CN108530536B (zh) * | 2018-03-27 | 2021-08-13 | 刘爽 | Cart-cd123及其制备与应用 |
| CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
| SG11202010116PA (en) | 2018-04-13 | 2020-11-27 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| US12227763B2 (en) | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| US12054558B2 (en) | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| EP3802619A1 (en) | 2018-06-08 | 2021-04-14 | F. Hoffmann-La Roche AG | Peptidic linker with reduced post-translational modification |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| WO2020007593A1 (en) | 2018-07-02 | 2020-01-09 | Cellectis | Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml |
| WO2020033585A1 (en) * | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12534532B2 (en) | 2018-10-26 | 2026-01-27 | Crage Medical Co., Limited | CLL1-targeting antibody and application thereof |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| SG11202105353PA (en) | 2018-12-01 | 2021-06-29 | Allogene Therapeutics Inc | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof |
| JP7642542B2 (ja) | 2018-12-18 | 2025-03-10 | ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド | Ｆｌｔ３アゴニスト抗体及びその使用 |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| WO2020180591A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Dll3 targeting chimeric antigen receptors and binding agents |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN113811327A (zh) * | 2019-03-11 | 2021-12-17 | 卢西德生物有限公司 | MUC1平行CAR(pCAR)治疗剂 |
| EP3938402A4 (en) * | 2019-03-15 | 2023-03-08 | Rutgers, The State University of New Jersey | CHIMERIC CD147 ANTIGEN RECEPTORS AND METHODS OF USE |
| WO2020191378A1 (en) | 2019-03-21 | 2020-09-24 | Allogene Therapeutics, Inc. | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY |
| JP7654557B2 (ja) * | 2019-03-27 | 2025-04-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法 |
| EP3952886A1 (en) | 2019-04-10 | 2022-02-16 | Elevatebio Technologies, Inc | Flt3-specific chimeric antigen receptors and methods of using the same |
| JP7664180B2 (ja) | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| KR20220004028A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN114222763A (zh) * | 2019-06-19 | 2022-03-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点 |
| CN112111013A (zh) * | 2019-06-22 | 2020-12-22 | 南京北恒生物科技有限公司 | 一种靶向claudin 18.2的通用型嵌合抗原受体T细胞、构建方法及其用途 |
| WO2021007266A1 (en) * | 2019-07-09 | 2021-01-14 | Hemogenyx Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| AU2020358863A1 (en) | 2019-10-03 | 2022-05-12 | Celyntra Therapeutics Sa | CRISPR systems with engineered dual guide nucleic acids |
| EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| AU2020415318A1 (en) | 2019-12-23 | 2022-07-14 | Cellectis | New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy |
| CA3168433A1 (en) | 2020-01-16 | 2021-07-22 | Allogene Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| JP2023514407A (ja) | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| IL296103A (en) | 2020-03-05 | 2022-11-01 | Neotx Therapeutics Ltd | Methods and compositions for treating cancer with immune cells |
| US20240058458A1 (en) * | 2020-03-06 | 2024-02-22 | Purdue Research Foundation | Methods, compounds, and compositions for modifying car-t cell activity |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| AU2021238320A1 (en) * | 2020-03-18 | 2022-09-22 | Elanco Us Inc. | Anti-IL4 receptor antibodies for veterinary use |
| IL296511A (en) | 2020-03-20 | 2022-11-01 | Lyell Immunopharma Inc | Novel recombinant cell surface markers |
| IL296755A (en) * | 2020-03-27 | 2022-11-01 | Univ Texas | Monoclonal antibodies targeting hsp70 and their therapeutic uses |
| US20230212613A1 (en) | 2020-05-06 | 2023-07-06 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
| US20230227525A1 (en) * | 2020-05-08 | 2023-07-20 | Smt Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| CN113735973B (zh) * | 2020-05-28 | 2023-05-09 | 中国科学院微生物研究所 | 一种抗SIRPα抗体及其应用 |
| EP4159763A4 (en) * | 2020-05-29 | 2024-06-12 | BrightPath Biotherapeutics Co., Ltd. | ANTI-CD73 ANTIBODIES AND USE THEREOF |
| EP4176261A1 (en) | 2020-07-03 | 2023-05-10 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
| EP4185610A2 (en) | 2020-07-21 | 2023-05-31 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| US20230248825A1 (en) | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| EP4192941A1 (en) * | 2020-08-07 | 2023-06-14 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered t cells |
| CN112079927B (zh) * | 2020-09-18 | 2021-12-28 | 西安桑尼赛尔生物医药有限公司 | 一种cd123结合蛋白、含其的car及其应用 |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN113980134B (zh) * | 2020-12-11 | 2022-05-31 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113248622B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 一种靶向cll1和nkg2d配体的双靶点嵌合抗原受体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| WO2022132720A1 (en) | 2020-12-14 | 2022-06-23 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| MX2023007901A (es) | 2020-12-31 | 2023-07-11 | Sanofi Sa | Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123. |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN112661816B (zh) * | 2021-01-13 | 2022-10-11 | 江西省人民医院 | 用于利妥昔单抗血药浓度检测的人工抗原及试剂盒 |
| AU2022212090A1 (en) | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| EP4298212A4 (en) | 2021-02-25 | 2026-04-15 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| KR20240007179A (ko) * | 2021-04-30 | 2024-01-16 | 셀렉티스 에스.에이. | 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포 |
| EP4419672A2 (en) | 2021-06-01 | 2024-08-28 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| JP2024526090A (ja) | 2021-06-15 | 2024-07-17 | アロジーン セラピューティクス，インコーポレイテッド | 同種ｃａｒ ｔ細胞の持続性を延長するための宿主ｃｄ７０＋アロ反応性細胞の選択的標的化 |
| CN115477704B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN115477705B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用 |
| EP4370676A2 (en) | 2021-06-18 | 2024-05-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| WO2023020471A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd123-targetting antibodies and uses thereof in cancer therapies |
| CA3230245A1 (en) | 2021-09-01 | 2023-03-09 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| EP4486881A1 (en) | 2022-03-01 | 2025-01-08 | Celyntra Therapeutics SA | Composition and methods for transgene insertion |
| CA3244596A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics, Inc. | Chimeric switch receivers for converting immunoactive signals into stimulation signals |
| EP4507794A1 (en) | 2022-04-11 | 2025-02-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
| IL317227A (en) | 2022-05-27 | 2025-01-01 | Sanofi Sa | Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering |
| JP2025525779A (ja) | 2022-07-29 | 2025-08-07 | アロジーン セラピューティクス，インコーポレイテッド | 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞 |
| WO2024051751A1 (zh) * | 2022-09-06 | 2024-03-14 | 河北森朗生物科技有限公司 | 抗cd123的纳米抗体、嵌合抗原受体及其应用 |
| US20260015409A1 (en) * | 2022-09-20 | 2026-01-15 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
| CN118240086B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| WO2024121385A1 (en) | 2022-12-09 | 2024-06-13 | Cellectis S.A. | Two-dose regimen in immunotherapy |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| CN117783521B (zh) * | 2023-11-23 | 2025-03-04 | 中国农业科学院兰州兽医研究所 | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 |
| CN119775421B (zh) * | 2023-12-21 | 2025-10-31 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025233825A1 (en) * | 2024-05-06 | 2025-11-13 | Janssen Pharmaceutica Nv | Enrichment of cells expressing a bird linker |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ATE430161T1 (de) | 2000-09-13 | 2009-05-15 | Multimmune Gmbh | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| BR0316101A (pt) | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US9982251B2 (en) | 2003-03-14 | 2018-05-29 | Cellectis S.A. | Large volume ex vivo electroporation method |
| NZ543635A (en) * | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2484340T3 (es) | 2003-12-05 | 2014-08-11 | Multimmune Gmbh | Anticuerpos anti hsp70 terapéuticos y diagnósticos |
| DK1716178T3 (da) * | 2004-02-16 | 2010-09-20 | Micromet Ag | Mindre immunogene bindingsmolekyler |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| GB0505971D0 (en) | 2005-03-23 | 2005-04-27 | Isis Innovation | Delivery of molecules to a lipid bilayer |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN101316610A (zh) * | 2005-09-22 | 2008-12-03 | 艾润·R·科恩 | T细胞受体恒定区的免疫原性片段及其衍生的肽 |
| WO2008102120A1 (en) | 2007-02-20 | 2008-08-28 | Oxford Nanopore Technologies Limited | Lipid bilayer sensor system |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP2211903A4 (en) * | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| US9487800B2 (en) | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| BR112013010362A2 (pt) * | 2010-10-27 | 2016-08-02 | Baxter Healthcare Sa | métodos para induzir uma tolerância imune a fviii, para fazer um peptídeo fviii, e para identificar uma célula t específica de peptídeo fvii, peptídeo, composição, e, proteína de fusão |
| EP2633040B1 (en) | 2010-10-27 | 2019-07-10 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| US8968539B2 (en) | 2011-03-08 | 2015-03-03 | Electronic Biosciences, Inc. | Methods for voltage-induced protein incorporation into planar lipid bilayers |
| CN110200997A (zh) * | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US9181308B2 (en) | 2011-03-28 | 2015-11-10 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| EP2694549B1 (en) | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US9285592B2 (en) | 2011-08-18 | 2016-03-15 | Google Inc. | Wearable device with input and output structures |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| KR102056932B1 (ko) * | 2011-10-10 | 2019-12-17 | 시티 오브 호프 | 메디토프와 메디토프-결합 항체 및 이들의 용도 |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| EP2750690B1 (en) * | 2011-11-15 | 2018-11-07 | The Walter and Eliza Hall Institute of Medical Research | Soluble mediator |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| MX2014010185A (es) | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| CA3205751A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN104507537A (zh) | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| TW201446794A (zh) * | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2897579T3 (es) * | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Métodos y composiciones para reducir la inmunosupresión por células tumorales |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| US20160296562A1 (en) | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| KR102348577B1 (ko) | 2013-11-22 | 2022-01-06 | 셀렉티스 | 면역요법을 위한 화학요법 약물 저항성 ｔ―세포들의 조작 방법 |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| CN113354744A (zh) * | 2013-12-20 | 2021-09-07 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| CA2943008C (en) * | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| WO2015158671A1 (en) * | 2014-04-14 | 2015-10-22 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| KR20170037625A (ko) * | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| BR112017011893A2 (pt) | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
| EP3283520B1 (en) | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9668192B2 (en) | 2015-10-12 | 2017-05-30 | Telefonaktiebolaget Lm Ericsson (Publ) | Cell boundary crossing in a unidirectional SFN for high speed trains |
-
2016
- 2016-01-25 ES ES16703448T patent/ES2869972T3/es active Active
- 2016-01-25 BR BR112017013981-2A patent/BR112017013981A2/pt active IP Right Grant
- 2016-01-25 AU AU2016212161A patent/AU2016212161A1/en not_active Abandoned
- 2016-01-25 CA CA2973532A patent/CA2973532A1/en not_active Abandoned
- 2016-01-25 US US15/546,604 patent/US20180000914A1/en not_active Abandoned
- 2016-01-25 KR KR1020177023447A patent/KR102661969B1/ko active Active
- 2016-01-25 JP JP2017557487A patent/JP6884709B2/ja active Active
- 2016-01-25 DK DK16703450.3T patent/DK3250606T3/da active
- 2016-01-25 RU RU2017129592A patent/RU2731543C2/ru active
- 2016-01-25 ES ES16703450T patent/ES2842212T3/es active Active
- 2016-01-25 MX MX2017009181A patent/MX381908B/es unknown
- 2016-01-25 AU AU2016212160A patent/AU2016212160B2/en active Active
- 2016-01-25 MX MX2017009349A patent/MX2017009349A/es unknown
- 2016-01-25 WO PCT/EP2016/051469 patent/WO2016120218A1/en not_active Ceased
- 2016-01-25 EP EP16701616.1A patent/EP3250602A1/en not_active Withdrawn
- 2016-01-25 MX MX2017009182A patent/MX389057B/es unknown
- 2016-01-25 AU AU2016212159A patent/AU2016212159A1/en not_active Abandoned
- 2016-01-25 EP EP16703449.5A patent/EP3250605A1/en not_active Ceased
- 2016-01-25 AU AU2016212162A patent/AU2016212162A1/en not_active Abandoned
- 2016-01-25 RU RU2017129591A patent/RU2732925C2/ru active
- 2016-01-25 JP JP2017557489A patent/JP6779909B2/ja active Active
- 2016-01-25 WO PCT/EP2016/051468 patent/WO2016120217A1/en not_active Ceased
- 2016-01-25 CN CN201680006922.0A patent/CN107438618A/zh active Pending
- 2016-01-25 CA CA2973524A patent/CA2973524A1/en not_active Abandoned
- 2016-01-25 CN CN202111329158.XA patent/CN113968915A/zh active Pending
- 2016-01-25 EP EP16703450.3A patent/EP3250606B1/en active Active
- 2016-01-25 JP JP2017557491A patent/JP2018504145A/ja active Pending
- 2016-01-25 RU RU2017129455A patent/RU2017129455A/ru not_active Application Discontinuation
- 2016-01-25 JP JP2017557488A patent/JP2018504143A/ja active Pending
- 2016-01-25 CA CA2973529A patent/CA2973529A1/en not_active Abandoned
- 2016-01-25 WO PCT/EP2016/051467 patent/WO2016120216A1/en not_active Ceased
- 2016-01-25 WO PCT/EP2016/051470 patent/WO2016120219A1/en not_active Ceased
- 2016-01-25 US US15/546,619 patent/US20180002427A1/en not_active Abandoned
- 2016-01-25 WO PCT/EP2016/051471 patent/WO2016120220A1/en not_active Ceased
- 2016-01-25 CN CN201680006992.6A patent/CN107531801B/zh active Active
- 2016-01-25 BR BR112017015453-6A patent/BR112017015453A2/pt not_active Application Discontinuation
- 2016-01-25 CN CN201680006972.9A patent/CN107406516B/zh active Active
- 2016-01-25 AU AU2016212158A patent/AU2016212158B2/en active Active
- 2016-01-25 EP EP16704136.7A patent/EP3250607A1/en not_active Withdrawn
- 2016-01-25 US US15/546,623 patent/US20180051089A1/en not_active Abandoned
- 2016-01-25 EP EP16703448.7A patent/EP3250604B1/en active Active
- 2016-01-25 DK DK16703448.7T patent/DK3250604T3/da active
- 2016-01-25 US US15/546,630 patent/US20180002435A1/en not_active Abandoned
- 2016-01-25 CN CN202111328553.6A patent/CN113968914A/zh active Pending
- 2016-01-25 US US15/546,633 patent/US11014989B2/en active Active
- 2016-01-25 CA CA2973525A patent/CA2973525C/en active Active
- 2016-01-25 JP JP2017557490A patent/JP2018504144A/ja not_active Withdrawn
- 2016-01-25 KR KR1020177021615A patent/KR102329836B1/ko active Active
- 2016-01-25 KR KR1020177023078A patent/KR20170135824A/ko not_active Withdrawn
-
2017
- 2017-06-15 IL IL252937A patent/IL252937B/en unknown
- 2017-06-19 IL IL253012A patent/IL253012A0/en unknown
- 2017-06-20 IL IL253049A patent/IL253049B/en unknown
-
2023
- 2023-10-05 US US18/481,797 patent/US20240228636A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504144A5 (https=) | ||
| JP2018504143A5 (https=) | ||
| JP2018504459A5 (https=) | ||
| JP7825000B2 (ja) | Ｈｅｒ３抗原結合性分子 | |
| ES2896921T3 (es) | Tratamiento y prevención del cáncer usando moléculas de unión al antígeno HER3 | |
| RU2017129592A (ru) | АНТИ-CLL1-СПЕЦИФИЧЕСКИЕ ОДНОЦЕПОЧЕЧНЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ (scCAR) ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| Ordóñez | Podoplanin: a novel diagnostic immunohistochemical marker | |
| US11325965B2 (en) | Single-domain VH H antibodies directed to norovirus GI.1 and GII.4 and their use | |
| US20210380697A1 (en) | Vista antigen-binding molecules | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| CN103827144B (zh) | 新的抗cxcr4抗体及其用于检测和诊断癌症的用途 | |
| JP2018029595A5 (https=) | ||
| KR20120051734A (ko) | 항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도 | |
| BR112012033406B1 (pt) | Anticorpos isolados e uso dos mesmos, hibridoma murino, ácido nucleico isolado, kit, bem como processos in vitro por imunocoloração para detecção da presença e/ou localização, determinação do nível de expressão, diagnóstico, determinação do prognóstico para o desenvolvimento, determinação do estado da forma ativada independente de ligante de cmet expresso em tumor em um indivíduo, e para determinação se uma desordem oncogênica é suscetível a um tratamento com um anticorpo anti-forma ativada independente de ligante de cmet | |
| CN103717620A (zh) | 用于检测和诊断癌症的抗体i-3859的用途 | |
| JP2021518137A5 (https=) | ||
| CN114773477B (zh) | 抗b7-h3抗体及其用途 | |
| WO2019086574A1 (en) | Cd47 and cd33 antigen-binding molecules | |
| EP2757376A1 (en) | Molecular marker for early indentification of pleural mesothelioma patients, and expression analysis method for same | |
| Sahin et al. | Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors | |
| WO2019110209A1 (en) | Cd47 and bcma/taci antigen-binding molecules | |
| CN109535255B (zh) | 一种抗人cd26抗体及其在检测试剂盒中的应用 | |
| CN101240021B (zh) | 抗人cdk5rap2蛋白的单克隆抗体及其应用 | |
| WO2007114550A1 (en) | A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same | |
| CN109022415B (zh) | PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用 |